Antiviral poly-and oligonucleotides
US5728518A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Aug 8, 1994 |
| Grant date | Mar 17, 1998 |
| Priority date | — |
| Expiry date | Aug 8, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Poly- and oligonucleotides which inhibit viral replication, particularly hepatitis virus replication, such as hepatitis B virus (HBV) replication, are disclosed. Preferred antiviral oligonucleotides include the following: an antiviral poly- or oligonucleotide which hybridizes to at least a portion of an RNA primer-binding region of a viral nucleic acid, preferably a DRII region of HBV DNA; an antiviral poly- or oligonucleotide which hybridizes to at least a portion of an RNA primer which binds a viral nucleic acid, preferably a DRII region of HBV DNA; an antiviral poly- or oligonucleotide which hybridizes to a hepatitis virus mRNA encoding a DNA polymerase, preferably an HBV mRNA; an antiviral poly- or oligonucleotide which hybridizes to a hepatitis virus mRNA encoding an envelope protein essential for viral attachment to a target cell, preferably an HBV mRNA encoding a pre-S1 protein; and an antiviral poly- or oligonucleotide which hybridizes to an encapsidation signal of a viral nucleic acid, preferably an HBV cis-encapsidation signal, thereby inhibiting encapsidation of the viral nucleic acid. The disclosed poly- or oligonucleotides can be used for detection of the presence of v…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.